Skip to main content

Advertisement

SpringerLink
Log in

The role of killer-cell immunoglobulin-like receptor (KIR) genes in susceptibility to inflammatory bowel disease: systematic review and meta-analysis

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Background

Inflammatory bowel disease (IBD) is a chronic inflammatory disease, which involves the gut and comprises of Crohn’s disease (CD) and ulcerative colitis (UC). Immune cells, including natural killer (NK) cells, play an important role in the pathogenesis of the disease. Killer immunoglobulin-like receptors (KIRs) are NK cell surface receptors, which ligate to the class I major histocompatibility complex (MHC) and have inhibitory or activating effects on the NK cells. The aim of this study was to perform a meta-analysis of the six studies evaluating the association in the polymorphisms of these KIR genes and the IBD risk (4 UC and 5 CD studies).

Methods

A systematic search was conducted in the electronic databases to find all the studies on the KIR gene polymorphism in IBD patients prior to December 2017. The odds ratio (OR) and 95% confidence interval (CI) were  used to find any association between KIR gene polymorphisms and the IBD risk.

Results

Following extraction of the data from the studies, which were screened by inclusion and exclusion criteria, collectively 432 patients and 886 controls for UC and 1677 patients and 1308 controls for CD were included in the meta-analysis. The statistical evaluation demonstrated positive associations between 2DL5 (OR=1.31, 95% CI=1.01–1.69) and 2DS1 (OR=1.33, 95% CI=1.01–1.76) members of KIR genes and UC risk, as well a negative association between 2DS3 gene and CD risk was detected (OR=0.74, 95% CI=0.60–0.90).

Conclusions

There are positive associations between 2DL5 and 2DS1 members of KIR genes and UC risk and a negative association between 2DS3 and CD risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Opt Gastroenterol. 2015;13:105–20.

    Article  Google Scholar 

  2. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.

    Article  PubMed  Google Scholar 

  3. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease, seminars in immunopathology, vol. 37. Berlin: Springer; 2015.

    Google Scholar 

  4. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744–52.

    Article  PubMed  CAS  Google Scholar 

  5. Ford AC, Moayyedi P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, et al. Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. Am J Gastroenterol. 2015;110:716–24.

    Article  PubMed  Google Scholar 

  6. De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.

    Article  PubMed  CAS  Google Scholar 

  7. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–40.

    Article  PubMed  CAS  Google Scholar 

  8. Steel A, Mela C, Lindsay J, Gazzard B, Goodier M. Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther. 2011;33:115–26.

    Article  PubMed  CAS  Google Scholar 

  9. Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44+ NKp46− and NKp44− NKp46+ natural killer cells in the intestinal mucosa of patients with Crohn’s disease. Gastroenterology. 2010;139:882–92.e3.

    Article  PubMed  CAS  Google Scholar 

  10. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–5.

    Article  PubMed  CAS  Google Scholar 

  11. Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity. 2001;15:363–74.

    Article  PubMed  CAS  Google Scholar 

  12. Falco M, Moretta L, Moretta A, Bottino C. KIR and KIR ligand polymorphism: a new area for clinical applications? HLA. 2013;82:363–73.

    CAS  Google Scholar 

  13. López-Hernández R, Campillo JA, Legaz I, Valdés M, Salama H, Boix F, et al. Killer immunoglobulin-like receptor (KIR) repertoire analysis in a Caucasian Spanish population with inflammatory bowel diseases. Microbiol Immunol. 2016;60:787–92.

    Article  PubMed  CAS  Google Scholar 

  14. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193.

    Article  PubMed  Google Scholar 

  15. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Jones D, Edgar R, Ahmad T, Cummings J, Jewell D, Trowsdale J, et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun. 2006;7:576–82.

    Article  PubMed  CAS  Google Scholar 

  17. Wilson TJ, Jobim M, Jobim LF, Portela P, Salim PH, Rosito MA, et al. Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn’s disease and ulcerative colitis. Hum Immunol. 2010;71:293–7.

    Article  PubMed  CAS  Google Scholar 

  18. Zhang H, Liu S, Liu Z, Li J. Expression of iKIR-HLA-Cw in patients with inflammatory bowel disease. Life Sci J. 2008;5:17–22.

    CAS  Google Scholar 

  19. Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T, et al. Susceptibility to Crohn’s disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics. 2009;61:663.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Díaz-Peña R, Vidal-Castiñeira JR, Moro-García MA, Alonso-Arias R, Castro-Santos P. Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn’s disease. Hum Immunol. 2016;77:104–9.

    Article  PubMed  CAS  Google Scholar 

  21. Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol. 2012;3:326.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA. 2005;102:13224–9.

    Article  PubMed  CAS  Google Scholar 

  23. Erer B, Takeuchi M, Ustek D, Tugal-Tutkun I, Seyahi E, Özyazgan Y, et al. Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet’s disease. Genes Immun. 2016;17:396.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Li X, Xia Q, Fan D, Cai G, Yang X, Wang L, et al. Association between KIR gene polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Hum Immunol. 2015;76:565–70.

    Article  PubMed  CAS  Google Scholar 

  25. García-León JA, Pinto-Medel MJ, García-Trujillo L, López-Gómez C, Oliver-Martos B, Prat-Arrojo I, et al. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol. 2011;48:1896–902.

    Article  PubMed  CAS  Google Scholar 

  26. Díaz-Peña R, Vidal-Castiñeira JR, Mulero J, Sánchez A, Queiro R, López-Larrea C. Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis. Clin Exp Immunol. 2015;180:201–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Suzuki Y, Hamamoto Y, Ogasawara Y, Ishikawa K, Yoshikawa Y, Sasazuki T, et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Investig Dermatol. 2004;122:1133–6.

    Article  PubMed  CAS  Google Scholar 

  28. Traherne JA, Jiang W, Valdes AM, Hollenbach JA, Jayaraman J, Lane JA, et al. KIR haplotypes are associated with late-onset type 1 diabetes in European–American families. Genes Immun. 2016;17:8–12.

    Article  PubMed  CAS  Google Scholar 

  29. Dastmalchi R, Farazmand A, Noshad S, Mozafari M, Mahmoudi M, Esteghamati A, et al. Polymorphism of killer cell immunoglobulin-like receptors (KIR) and their HLA ligands in Graves’ disease. Mol Biol Rep. 2014;41:5367–74.

    Article  PubMed  CAS  Google Scholar 

  30. Mahmoudi M, Fallahian F, Sobhani S, Ghoroghi S, Jamshidi A, Poursani S, et al. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Clin Rheumatol. 2017;36:853–62.

    Article  PubMed  Google Scholar 

  31. Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277–300.

    Article  PubMed  CAS  Google Scholar 

  32. Yusa S, Catina T, Campbell K. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol (Baltimore: 1950). 2004;172:7385–92.

    CAS  Google Scholar 

  33. VandenBussche C, Mulrooney T, Frazier W, Dakshanamurthy S, Hurley C. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun. 2009;10:162–74.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a Grant from Tehran University of Medical Sciences (Grant No. 92-02-41-23195).

Author information

Authors and Affiliations

  1. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Anwar Fathollahi, Saeed Aslani, Shayan Mostafaei & Mahdi Mahmoudi

  2. Department of Medical Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Anwar Fathollahi

  3. Department of Community Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Shayan Mostafaei

  4. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  5. Departments of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  6. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Nima Rezaei

  7. Rheumatology Expert Group (REG), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Mahdi Mahmoudi

Authors
  1. Anwar Fathollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Aslani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shayan Mostafaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahdi Mahmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahdi Mahmoudi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Responsible Editor: John Di Battista.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fathollahi, A., Aslani, S., Mostafaei, S. et al. The role of killer-cell immunoglobulin-like receptor (KIR) genes in susceptibility to inflammatory bowel disease: systematic review and meta-analysis. Inflamm. Res. 67, 727–736 (2018). https://doi.org/10.1007/s00011-018-1162-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-018-1162-7

Keywords

Search

Navigation